Molecule
Secnidazole is a nitroimidazole antimicrobial indicated for treatment of bacterial vaginosis in female patients 12 years of age and older, among other approved uses. It is available as granules for oral use. MedsAcross supplies Secnidazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SOLOSEC ® is a nitroimidazole antimicrobial indicated for: Treatment of bacterial vaginosis in female patients 12 years of age and older. Treatment of trichomoniasis in patients 12 years of age and older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Source: US FDA prescribing information
SOLOSEC is a nitroimidazole antimicrobial drug.
Source: US FDA prescribing information
Bacterial Vaginosis (female patients 12 years of age and older): Administer a single 2-gram packet of granules once orally, without regard to the timing of meals. Trichomoniasis (patients 12 years of age and older): Administer a single 2-gram packet of granules once orally, without regard to the timing of meals. Treat sexual partners with the same dose and at the same time. Sprinkle entire contents of packet onto applesauce, yogurt or pudding and consume all of the mixture within 30 minutes without chewing or crunching the granules. A glass of water may be taken after the administration of SOLOSEC to aid in swallowing. SOLOSEC is not intended to be dissolved in any liquid.
Source: US FDA prescribing information
4. CONTRAINDICATIONS SOLOSEC is contraindicated: In patients who have shown hypersensitivity to secnidazole, or other nitroimidazole derivatives. In patients with Cockayne syndrome: Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to secnidazole, in patients with Cockayne syndrome. History of hypersensitivity to secnidazole, or other nitroimidazole derivatives. Patients with Cockayne syndrome.
Source: US FDA prescribing information
Vulvovaginal Candidiasis: This may develop with SOLOSEC and require treatment with an antifungal agent. Potential Risk for Carcinogenicity: Carcinogenicity has been seen in mice and rats treated chronically with nitroimidazole derivatives, which are structurally related to secnidazole. It is unclear if the positive tumor findings in lifetime rodent studies indicate a risk to patients taking a single dose of SOLOSEC to treat bacterial vaginosis. Avoid chronic use.
Source: US FDA prescribing information
The following important adverse reactions are discussed in greater detail in other sections of labeling: Vulvovaginal Candidiasis [Warnings and Precautions ] Bacterial Vaginosis: Most common adverse reactions observed in clinical trials of bacterial vaginosis (incidence ≥ 2%) were vulvovaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus. Trichomoniasis: Most common adverse reaction observed in the clinical trial of trichomoniasis (incidence ≥ 2%) was vulvovaginal candidiasis.
Source: US FDA prescribing information
Oral Contraceptives There was no clinically significant drug interaction between secnidazole and the combination oral contraceptive, ethinyl estradiol plus norethindrone. SOLOSEC can be co-administered with combination oral contraceptives (e.g., ethinyl estradiol plus norethindrone).
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Secnidazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Solosec 2 g/4.8 g granulesOral | Evofem | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 15 September 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Secnidazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Secnidazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Secnidazole, including Solosec.
Yes. The US FDA first approved Secnidazole on 15 September 2017, according to Drugs@FDA.
No listed presentation of Secnidazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Secnidazole is classified under ATC code P01AB07 (Secnidazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.